MOTS C Community Reports
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
How can it help me?
Wiki article — community perspective
Companion raw digest:
Evidence tier: throughout
Last updated: 2026-07-10
Cross-refs: *peptides/ss-31* · *peptides/semaglutide* · *peptides/tirzepatide* · *peptides/retatrutide*
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
What should I avoid combining — and what's synergistic?
MOTS C Community Reports doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for MOTS C Community Reports yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Wiki article — community perspective
Companion raw digest:
Evidence tier: throughout
Last updated: 2026-07-10
Cross-refs: *peptides/ss-31* · *peptides/semaglutide* · *peptides/tirzepatide* · *peptides/retatrutide*
Who reports the strongest results
Performance-oriented users, biohackers, and anyone managing GLP-1 fatigue. MOTS-c’s two dominant community applications are: (1) cardiorespiratory performance improvement described as “a third lung appearing,” and (2) energy restoration for users whose GLP-1 agonists (semaglutide, tirzepatide, retatrutide) are causing fatigue.
What the community actually says
“The third lung” — the signature experience
The defining community description: a subjective improvement in aerobic capacity felt as something that wasn’t there before. Not stimulant energy, not forced performance — users describe it as the ceiling going up.
- Lower perceived effort at the same cardio output
- Reduced breathlessness at exertion levels that previously caused it
- Faster recovery between high-intensity intervals
- “Being able to push through intervals that used to stop me” — the most repeated framing
Typically appears within the first 1–2 weeks of use. It’s not gradual — users often report a specific workout where they noticed it.
GLP-1 fatigue rescue
A consistent and growing application: users on semaglutide, tirzepatide, or retatrutide who experience fatigue (a known side effect of GLP-1 agonists in some users) find MOTS-c counteracts this. Energy returns to baseline and sometimes beyond.
This is one of the few peptides with a strong community signal specifically positioned as a combination optimization rather than a standalone protocol.
Baseline energy elevation
Beyond the cardio effect: a sustained “floor went up” experience across everyday activities. Not an acute spike, not stimulant-like. Users describe less total fatigue, more baseline capacity for daily activity.
The injection site challenge — and its fix
Near-universal early experience: welts. Raised, red, warm injection site reactions are reported by the vast majority of new MOTS-c users.
The community fix: Reconstitute MOTS-c in isotonic bacteriostatic water (rather than standard BAC water). The osmolarity difference dramatically reduces welt severity. This is now the first piece of advice in every “bad welts” thread. Anyone getting severe injection site reactions should switch reconstitution solution before abandoning the peptide.
Folate depletion — emerging community concern
Cluster of users running post-cycle bloodwork independently discovered low folate after sustained MOTS-c use. Proposed mechanism: MOTS-c’s influence on one-carbon/methylation metabolism may increase folate demand.
Community practice: Supplement L-methylfolate (active form) from the first day of the cycle. Adopted as precautionary best practice pending more data.
Protocol as used by the community
Dose: 10–15 mg per injection (note: this is higher by mass than most peptides)
Frequency: 3× per week is most common; daily use for biohackers willing to accept the cost
Route: SubQ; isotonic BAC water reconstitution
Stack: SS-31 + MOTS-c is the “mito stack” — complementary mechanisms (SS-31 at mitochondrial membrane; MOTS-c at signaling/transcriptional level). See *peptides/ss-31*.
WADA ban (January 2025)
MOTS-c was added to the WADA S0 prohibited list in January 2025. Competitive tested athletes must not use it. Non-athletes are unaffected. Community reaction: “if WADA cares, it works.”
Cross-references
*peptides/ss-31*— the complementary mito stack partner*peptides/semaglutide*·*peptides/tirzepatide*·*peptides/retatrutide*— GLP-1 agents that sometimes cause fatigue; MOTS-c as the energy rescue
Commercial note
MOTS-c is available through Alyve — use code OHM-15 at checkout for 15% off.